Analysis of bone mineral profile and TSH in early non-dialysis stages of chronic kidney disease - a retrospective cross-sectional study
Article Sidebar
Main Article Content
https://orcid.org/0009-0000-1361-7200
Karthick Elango
https://orcid.org/0009-0006-3358-7532
Sathya Selvarajan
https://orcid.org/0000-0002-6390-1522
Abstract
The objective of this study is to analyse the levels of Thyroid stimulating hormone (TSH) and the Bone Mineral Profile (Vitamin D, Parathyroid hormone (PTH), calcium, phosphorus, magnesium, and alkaline phosphatase [ALP]) levels in the early stages of chronic kidney disease (CKD) based on Glomerular filtration rate (GFR). A retrospective analysis was conducted involving 247 CKD patients admitted to the nephrology department at Sri Ramachandra Medical College Hospital from January to June 2022. The estimated GFR (eGFR) was calculated utilizing the CKD-EPI formula provided by the National Kidney Foundation. All biomarkers were analysed using automated platforms. The baseline ages for the three groups were 52.5, 68, and 66.5 years respectively (p<0.001). The comparative analysis revealed statistically significant differences solely among Vitamin D, creatinine, PTH, and phosphorus across the three groups. Further correlation analysis demonstrated changes in bore significant correlations with only creatinine, vitamin D, and PTH. This study concludes that in the early stages of CKD, vitamin D followed by PTH appears to be the earliest biomarker for assessing CKD-Mineral and Bone Disorder (CKD-MBD) occurring prior to any alterations in calcium and phosphate levels. As such, early consideration of supplementation may prove beneficial in mitigating disease progression and preventing cardiovascular complications.
Downloads
Article Details
Copyright (c) 2024 Immaculate Rithika Rajan, Karthick Elango, Sathya Selvarajan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
KDIGO 2023 clinical practice guideline for the evaluation and management of chronic kidney disease 2023. https://kdisgo.org/wp-content/uploads/2017/02/KDIGO-2023-CKD-Guideline-Public-Review-Draft_5-July_2023.pdf
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7–11. https://doi.org/10.1016/j.kisu.2021.11.003
Vahdat S. (2020). Vitamin D and kidney diseases: A narrative review. Int J Prev Med. 2020:11:195. https://doi.org/10.4103/ijpvm.IJPVM_54_19
Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, Bansal V, Rosas SE, Nigwekar S, Yee J, Kramer H. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2017;70(6):737-751. https://doi.org/10.1053/j.ajkd.2017.07.019
Narasaki Y, Sohn P, Rhee CM. The interplay between thyroid dysfunction and kidney disease. Semin Nephrol. 2021;41(2):133-143. https://doi.org/10.1016/j.semnephrol.2021.03.008
Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157-72. https://doi.org/10.1161/CIRCULATIONAHA.120.050686
Rhee CM. The interaction between thyroid and kidney disease: an overview of the evidence. Curr Opin Endocrinol Diabetes Obes. 2016;23(5):407-15. https://doi.org/10.1097/med.0000000000000275
Kang EW, Nam JY, Yoo TH, Shin SK, Kang SW, Han DS, Han SH. Clinical implications of subclinical hypothyroidism in continuous ambulatory peritoneal dialysis patients. Am J Nephrol. 2008;28(6):908-13. https://doi.org/10.1159/000141933
Rhee CM, Kim S, Gillen DL, Oztan T, Wang J, Mehrotra R, Kuttykrishnan S, Nguyen DV, Brunelli SM, Kovesdy CP, Brent GA. Association of thyroid functional disease with mortality in a national cohort of incident hemodialysis patients. J Clin Endocrinol Metab. 2015;100(4):1386-95 https://doi.org/10.1210/jc.2014-4311
Lo JC, Chertow GM, Go AS, Hsu CY. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int. 2005;67(3):1047-52. https://doi.org/10.1111/j.1523-1755.2005.00169.x
Targher G, Chonchol M, Zoppini G, Salvagno G, Pichiri I, Franchini M, Lippi G. Prevalence of thyroid autoimmunity and subclinical hypothyroidism in persons with chronic kidney disease not requiring chronic dialysis. Clin Chem Lab Med. 2009;47(11):1367-71. https://doi.org/10.1515/CCLM.2009.304
Kim EO, Lee IS, Choi YA, Lee SJ, Chang YK, Yoon HE, Jang YS, Lee JM, Kim HS, Yang CW, Kim SY. Unresolved subclinical hypothyroidism is independently associated with the progression of chronic kidney disease. Int J Med Sci. 2014;11(1):52–59. https://doi.org/10.7150/ijms.7186
Chandra A. Prevalence of hypothyroidism in patients with chronic kidney disease: a cross-sectional study from North India. Kidney Res Clin Pract. 2016; 35(3): 165–168. https://doi.org/10.1016/j.krcp.2016.06.003
Ansari I, Kumar S, Acharya S, Agrawal S, Saboo K. Thyroid dysfunction at different stages of chronic kidney disease: a cross-sectional study at a rural teaching college in central India. Cureus. 2023;15(7):e42130. https://doi.org/10.7759%2Fcureus.42130
Delanaye P, Souberbielle JC, Lafage-Proust MH, Jean G, Cavalier E. Can we use circulating biomarkers to monitor bone turnover in CKD hemodialysis patients? Hypotheses and facts. Nephrol Dial Transplant. 2014;29(5):997-1004. https://doi.org/10.1093/ndt/gft275
Waziri B, Duarte R, Naicker S. Chronic kidney disease–mineral and bone disorder (CKD-MBD): current perspectives. Int J Nephrol Renovasc Dis. 2019;12:263-276. https://doi.org/10.2147%2FIJNRD.S191156
Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber Jr MJ, Simon JF, Srinivas TR, Nally Jr JV. Low 25-hydroxyvitamin d levels and mortality in non–dialysis-dependent CKD. Am J Kidney Dis. 2011; 58(4): 536–543. https://doi.org/10.1053/j.ajkd.2011.04.028
Molina P, Górriz JL, Molina MD, Beltrán S, Vizcaíno B, Escudero V, Kanter J, Ávila AI, Bover J, Fernández E, Nieto J. What is the optimal level of vitamin D in non-dialysis chronic kidney disease population?. World J Nephrol. 2016;5(5):471–481. https://doi.org/10.5527%2Fwjn.v5.i5.471
Ureña-Torres P, Metzger M, Haymann JP, Karras A, Boffa JJ, Flamant M, Vrtovsnik F, Gauci C, Froissart M, Houillier P, Stengel B. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am J Kidney Dis. 2011;58(4):544-53. https://doi.org/10.1053/j.ajkd.2011.04.029
Franca Gois PH, Wolley M, Ranganathan D, Seguro AC. Vitamin D deficiency in chronic kidney disease: recent evidence and controversies. Int J Environ Res Public Health. 2018 Aug;15(8):1773. https://doi.org/10.3390/ijerph15081773
Bricker NS. On the pathogenesis of the uremic state: An exposition of the “trade-off hypothesis”. N Engl J Med. 1972 May 18;286(20):1093-9.https://doi.org/10.1056/nejm197205182862009
Isakova T, Wahl P, Vargas G, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L. FGF23, PTH and phosphorus metabolism in the chronic renal insufficiency cohort. Kidney Int. 2011 Jun;79(12):1370–1378. https://doi.org/10.1038/ki.2011.47
Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF‐23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Journal of bone and mineral research. J Bone Miner Res. 2004 Mar;19(3):429-35. https://doi.org/10.1359/jbmr.0301264
